Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. More Details
Excellent balance sheet and slightly overvalued.
Share Price & News
How has Seres Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MCRB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: MCRB's weekly volatility has decreased from 56% to 9% over the past year.
7 Day Return
1 Year Return
Return vs Industry: MCRB exceeded the US Biotechs industry which returned 18.9% over the past year.
Return vs Market: MCRB exceeded the US Market which returned 38.2% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Seres Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StBroker Revenue Forecasts For Seres Therapeutics, Inc. (NASDAQ:MCRB) Are Surging Higher
2 months ago | Simply Wall StIs Seres Therapeutics (NASDAQ:MCRB) Using Debt In A Risky Way?
4 months ago | Simply Wall StImagine Holding Seres Therapeutics (NASDAQ:MCRB) Shares While The Price Zoomed 681% Higher
Is Seres Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MCRB ($21.83) is trading below our estimate of fair value ($266.29)
Significantly Below Fair Value: MCRB is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MCRB is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: MCRB is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MCRB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MCRB is overvalued based on its PB Ratio (13.9x) compared to the US Biotechs industry average (3.4x).
How is Seres Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MCRB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MCRB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MCRB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MCRB's revenue (62.6% per year) is forecast to grow faster than the US market (9.5% per year).
High Growth Revenue: MCRB's revenue (62.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MCRB's Return on Equity is forecast to be high in 3 years time
How has Seres Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MCRB is currently unprofitable.
Growing Profit Margin: MCRB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MCRB is unprofitable, but has reduced losses over the past 5 years at a rate of 0.2% per year.
Accelerating Growth: Unable to compare MCRB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MCRB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).
Return on Equity
High ROE: MCRB has a negative Return on Equity (-72.87%), as it is currently unprofitable.
How is Seres Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: MCRB's short term assets ($252.0M) exceed its short term liabilities ($47.9M).
Long Term Liabilities: MCRB's short term assets ($252.0M) exceed its long term liabilities ($114.1M).
Debt to Equity History and Analysis
Debt Level: MCRB's debt to equity ratio (17.5%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if MCRB's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MCRB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MCRB has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 23.8% each year.
What is Seres Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MCRB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MCRB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MCRB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MCRB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MCRB's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Eric Shaff (44 yo)
Mr. Eric D. Shaff, M.B.A., serves as President and Chief Executive Officer of Seres Therapeutics, Inc. since January 15, 2019 and serves as its Director since January 2019. He served as Chief Operating Off...
CEO Compensation Analysis
Compensation vs Market: Eric's total compensation ($USD3.14M) is about average for companies of similar size in the US market ($USD3.73M).
Compensation vs Earnings: Eric's compensation has increased whilst the company is unprofitable.
Experienced Management: MCRB's management team is considered experienced (2.4 years average tenure).
Experienced Board: MCRB's board of directors are considered experienced (5.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.3%.
Seres Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Seres Therapeutics, Inc.
- Ticker: MCRB
- Exchange: NasdaqGS
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.001b
- Shares outstanding: 91.68m
- Website: https://www.serestherapeutics.com
Number of Employees
- Seres Therapeutics, Inc.
- 200 Sidney Street
- 4th Floor
- United States
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/20 14:55|
|End of Day Share Price||2021/06/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.